Mexidol® (a trade name for emoxypine succinate) is a nootropic drug widely used in Russian neurology. It was developed in the Soviet Union in the beginning of 1980s.

Mexidol has a wide spectrum of pharmacological action. One of its most important properties is pronounced antioxidant effect and the ability to restore neurotransmitter balance and receptor complex functions.

It has an atypical pharmacology, as it does not bind to any specific receptor. Instead, Emoxypine succinate does modulate the function of membrane receptors, ion channels, and ligand-receptor complexes. Mexidol interacts with benzodiazepine, GABA, and acetylcholine receptor complexes, increasing their sensitivity to ligands.

Emoxypine inhibits the process of lipid peroxidation and regulates nitric oxide levels in the brain. Another part of its antioxidant action is the increase of the activity of endogenous antioxidants such as superoxide dismutase.

An important fact to mention is that besides neurologic practice, Mexidol is also used in cardiology. It does improve the functional condition of the ischemic myocardium and restore myocardial contractility.

The indications for use are:

  • Cerebrovascular disorders;
  • Traumatic brain injuries;
  • Encephalopathies;
  • Cognitive disorders of atherosclerotic origin;
  • Anxiety disorders;
  • Ischemic heart disease;
  • Alcohol abstinence syndrome;
  • Asthenic conditions (chronic fatigue).

Recommended dosage is 125-250mg of Mexidol three times a day. The length of the treatment course is 2-6 weeks.

Contraindications for use are renal and liver insufficiency, hypersensitivity to the drug and pregnancy or lactation.

Possible side effects are digestive problems and allergic reactions.